Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by MrMonkon Jan 12, 2016 9:40pm
234 Views
Post# 24452342

Chat with Robert Wares

Chat with Robert WaresSpoke with Bob Wares via phone earlier tonight.  I can't get into nitty-gritty details, but the NioGold deal with Oban was mainly "forced" by Wexford Capital (high-level: Wexfod owned around 19% of the float - needed to sell their NioGold shares to raise capital, which led to the Oban deal).  This Oban deal was in the best interest of NioGold shareholders in light of the Wexford situation, and Oban stepped up to the plate with a fair and reasonable offer (also happened that the deal made a lot of sense for Oban; note that Bob Wares is on their board and owns Oban shares).

The key takeaway from the discussion with Bob was that if you still believe in Marban, then hold your NioGold shares and let them convert to Oban shares.  Oban actually offers comparable upside to what we had with NioGold - they still have the Marban project (which they will continue to develop, even with the current dismal gold price; they will focus on adding ounces) plus they have other promising projects and more to come.  We get to have our cake and eat it too - we get a good entry price on Oban, Marban is still very much in play, we get other Oban projects as well, and the situation has actually been de-risked (Niogold will likely have been out of cash by late this year, after the PEA; Oban has plenty of cash in the till, and the management team to execute its strategy).  The argument can easily be made that holding NioGold shares was substantially more risky than holding Oban shares.

If you still see the potential in Marban and like the people backing Oban, hold on for a future cash-out.  If the new reality isn't sitting well with you, take your chips off the table.  Simple as that.

- MM
<< Previous
Bullboard Posts
Next >>